TOPICAL BENZIMIDAZOLE FORMULATIONS AND METHODS FOR USE IN TREATING INFLAMMATORY DERMATOSES
Compositions and methods for treating and preventing inflammatory and autoimmune skin conditions, particularly rosacea, using one or more topically applied benzimidazole compounds in a pharmaceutically acceptable carrier for use on skin. A preferred benzimidazole compound comprises mebendazole. A tr...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Issa, Naiem T McCook, John P Jimenez, Joaquin J |
| description | Compositions and methods for treating and preventing inflammatory and autoimmune skin conditions, particularly rosacea, using one or more topically applied benzimidazole compounds in a pharmaceutically acceptable carrier for use on skin. A preferred benzimidazole compound comprises mebendazole. A treatment composition preferably comprises 0.05-0.20 weight percent mebendazole, and may comprise up to 20.0% mebendazole, in an aqueous or non-aqueous carrier or vehicle comprising a cream, gel, lotion, liquid, emulsion, microemulsion, aerosol spray, non-aerosol spray, serum, solution, suspension, or ointment and is applied at least once daily over a treatment period of at least two weeks to result in a reduction of cutaneous cytotoxic CD+8 T-cells, papules, pustules, swelling, appearance of redness or inflammation, and/or itchiness in the affected area compared to pre-treatment levels. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2024423959A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2024423959A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2024423959A13</originalsourceid><addsrcrecordid>eNqNirsKwjAUQLs4iPoPF5wFTevQ8drc2EAeksfQLKVInEQL9f-xBT_A6Rw4Z12kYG-yQQUXMklqyTFZRSCs01FhkNZ4QMNBU2gt90uA6AmkgeBoHsx1dqFQawzWdcDJLebJb4vVY3hOeffjptgLCk17yOO7z9M43PMrf_ro2ZFVFSvrc42n8r_rC1eQMzs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>TOPICAL BENZIMIDAZOLE FORMULATIONS AND METHODS FOR USE IN TREATING INFLAMMATORY DERMATOSES</title><source>esp@cenet</source><creator>Issa, Naiem T ; McCook, John P ; Jimenez, Joaquin J</creator><creatorcontrib>Issa, Naiem T ; McCook, John P ; Jimenez, Joaquin J</creatorcontrib><description>Compositions and methods for treating and preventing inflammatory and autoimmune skin conditions, particularly rosacea, using one or more topically applied benzimidazole compounds in a pharmaceutically acceptable carrier for use on skin. A preferred benzimidazole compound comprises mebendazole. A treatment composition preferably comprises 0.05-0.20 weight percent mebendazole, and may comprise up to 20.0% mebendazole, in an aqueous or non-aqueous carrier or vehicle comprising a cream, gel, lotion, liquid, emulsion, microemulsion, aerosol spray, non-aerosol spray, serum, solution, suspension, or ointment and is applied at least once daily over a treatment period of at least two weeks to result in a reduction of cutaneous cytotoxic CD+8 T-cells, papules, pustules, swelling, appearance of redness or inflammation, and/or itchiness in the affected area compared to pre-treatment levels.</description><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20241226&DB=EPODOC&CC=US&NR=2024423959A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20241226&DB=EPODOC&CC=US&NR=2024423959A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Issa, Naiem T</creatorcontrib><creatorcontrib>McCook, John P</creatorcontrib><creatorcontrib>Jimenez, Joaquin J</creatorcontrib><title>TOPICAL BENZIMIDAZOLE FORMULATIONS AND METHODS FOR USE IN TREATING INFLAMMATORY DERMATOSES</title><description>Compositions and methods for treating and preventing inflammatory and autoimmune skin conditions, particularly rosacea, using one or more topically applied benzimidazole compounds in a pharmaceutically acceptable carrier for use on skin. A preferred benzimidazole compound comprises mebendazole. A treatment composition preferably comprises 0.05-0.20 weight percent mebendazole, and may comprise up to 20.0% mebendazole, in an aqueous or non-aqueous carrier or vehicle comprising a cream, gel, lotion, liquid, emulsion, microemulsion, aerosol spray, non-aerosol spray, serum, solution, suspension, or ointment and is applied at least once daily over a treatment period of at least two weeks to result in a reduction of cutaneous cytotoxic CD+8 T-cells, papules, pustules, swelling, appearance of redness or inflammation, and/or itchiness in the affected area compared to pre-treatment levels.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNirsKwjAUQLs4iPoPF5wFTevQ8drc2EAeksfQLKVInEQL9f-xBT_A6Rw4Z12kYG-yQQUXMklqyTFZRSCs01FhkNZ4QMNBU2gt90uA6AmkgeBoHsx1dqFQawzWdcDJLebJb4vVY3hOeffjptgLCk17yOO7z9M43PMrf_ro2ZFVFSvrc42n8r_rC1eQMzs</recordid><startdate>20241226</startdate><enddate>20241226</enddate><creator>Issa, Naiem T</creator><creator>McCook, John P</creator><creator>Jimenez, Joaquin J</creator><scope>EVB</scope></search><sort><creationdate>20241226</creationdate><title>TOPICAL BENZIMIDAZOLE FORMULATIONS AND METHODS FOR USE IN TREATING INFLAMMATORY DERMATOSES</title><author>Issa, Naiem T ; McCook, John P ; Jimenez, Joaquin J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2024423959A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2024</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>Issa, Naiem T</creatorcontrib><creatorcontrib>McCook, John P</creatorcontrib><creatorcontrib>Jimenez, Joaquin J</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Issa, Naiem T</au><au>McCook, John P</au><au>Jimenez, Joaquin J</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>TOPICAL BENZIMIDAZOLE FORMULATIONS AND METHODS FOR USE IN TREATING INFLAMMATORY DERMATOSES</title><date>2024-12-26</date><risdate>2024</risdate><abstract>Compositions and methods for treating and preventing inflammatory and autoimmune skin conditions, particularly rosacea, using one or more topically applied benzimidazole compounds in a pharmaceutically acceptable carrier for use on skin. A preferred benzimidazole compound comprises mebendazole. A treatment composition preferably comprises 0.05-0.20 weight percent mebendazole, and may comprise up to 20.0% mebendazole, in an aqueous or non-aqueous carrier or vehicle comprising a cream, gel, lotion, liquid, emulsion, microemulsion, aerosol spray, non-aerosol spray, serum, solution, suspension, or ointment and is applied at least once daily over a treatment period of at least two weeks to result in a reduction of cutaneous cytotoxic CD+8 T-cells, papules, pustules, swelling, appearance of redness or inflammation, and/or itchiness in the affected area compared to pre-treatment levels.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_US2024423959A1 |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | TOPICAL BENZIMIDAZOLE FORMULATIONS AND METHODS FOR USE IN TREATING INFLAMMATORY DERMATOSES |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T13%3A13%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Issa,%20Naiem%20T&rft.date=2024-12-26&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2024423959A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |